Skip to main content
Figure 4 | Molecular Medicine

Figure 4

From: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Figure 4

Neuropathic symptoms as assessed by PainDetect are reduced significantly by ARA 290 administration. Time-dependent changes in the total PainDetect score showed a significant improvement in the ARA 290 group (filled circles) compared with placebo (open circles; p = 0.03; repeated measures ANOVA). This corresponds to an ∼18% change and ∼23% change from the baseline scores at d 28 and d 56 respectively for the ARA 290 group.

Back to article page